Biotech entity
Of the tracked stories, 2 of 2 also mention Protagonist Therapeutics, the most common co-covered peer. Across a 110-day span, the pace is roughly 0.1 stories per week. They are less corroborated than the beat average, carrying 2 original sources each against 3.4 for the same window.
Last mentioned: Jun 14, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention Protagonist Therapeutics, the most common co-covered peer. Across a 110-day span, the pace is roughly 0.1 stories per week. They are less corroborated than the beat average, carrying 2 original sources each against 3.4 for the same window. At 6.5, the average consequence score sits above the same-window beat average of 6.1. Coverage clusters in fda-approval, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Biotech stories that mention Rusfertide, published between February 25, 2026 and June 14, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 400 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Rusfertide. Shared-story counts are live from our verified record — not editorial picks.
Protagonist Therapeutics has transitioned from binary clinical risk to execution risk, with ICOTYDE's FDA approval and rusfertide's Priority Review. Backed by $620 million in cash, the company's validated peptide platform and royalty-based revenue model offer a compelling biotech investment thesis.
Protagonist Therapeutics has seen its share price skyrocket by 120% following significant clinical and regulatory milestones, yet a major institutional investor has disclosed a $170 million exit. This divergence highlights a classic 'sell the news' moment or strategic rebalancing amidst a period of high valuation for the peptide-based drug developer.
Source: fool.com · finance.yahoo.com
Rusfertide is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
